计提商誉减值 步长制药2024年业绩预亏

Core Viewpoint - Shandong Buchang Pharmaceutical Co., Ltd. is expected to report a net profit loss of approximately 4.28 billion to 8.08 billion yuan for the year 2024, primarily due to reduced sales from certain products being restricted by medical insurance policies and a shift in revenue structure [1][2]. Group 1: Financial Performance - The company plans to recognize an additional goodwill impairment of approximately 700 million to 1 billion yuan for its acquisitions of Tonghua Guhong Pharmaceutical Co., Ltd. and Jilin Tiancai Pharmaceutical Co., Ltd. [2] - As of the end of 2022, the company had already recognized a goodwill impairment of 3.07 billion yuan related to these acquisitions [1]. - The total goodwill value for Tonghua Guhong and Jilin Tiancai after the latest impairment will be 1.329 billion yuan [1]. Group 2: Product Performance - The company's core product, Naoxin Tong capsules, has seen a price reduction, with new prices set at 19.90 yuan, 26.26 yuan, and 38.81 yuan for different specifications [2]. - Naoxin Tong capsules, along with Weixin Granules and Danhong Injection, are the company's three exclusive products that significantly contribute to its revenue [3]. - In the first half of 2024, the combined sales revenue from these three products was 2.57 billion yuan, while their total sales revenue for 2023 was 7.428 billion yuan [3].